Answers are grounded in this paper and cite their sources.
Urinary microRNAs (miRNAs) are candidate non-invasive markers for distinguishing prostate cancer (PCa) from benign prostatic hyperplasia (BPH), but differences found in a single cohort often fail to recur in another. In this exploratory study, we sequenced small RNA from whole urine of two independently recruited cohorts of 7 and 25 subjects and examined how consistently PCa-versus-BPH differences recurred across them, using molecule counts that retain the orientation of each sequencing read. Fold changes of the miRNAs measured in both cohorts were broadly correlated, and 25 miRNAs differed significantly in both with the same direction; the largest decreases in PCa involved miRNAs enriched in leukocytes. An eight-miRNA score defined in the first cohort separated PCa from BPH in the second and discriminated better than serum prostate-specific antigen in a small subset with available values, an encouraging result to be confirmed in larger cohorts; these results are consistent with the original quantification and remain so after accounting for recruitment centre. Directions agreed only partly with public urine and serum data and were largely opposite to tumour tissue, consistent with whole urine reflecting several cellular sources. These hypothesis-generating findings require confirmation in larger, prospectively recruited cohorts with orthogonal assays.
No takes yet. Share an insight, caveat, or question.
Ragusa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: